Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction A comprehensive analysis of the immune cell infiltrate collected from pleural fluid and from biopsy specimens of malignant pleural mesothelioma (MPM) may contribute to understanding the immune-evasion mechanisms related to tumor progression, aiding in differential diagnosis and potential prognostic stratification. Until now such approach has not routinely been verified. Methods We enrolled 275 patients with an initial clinical diagnosis of pleural effusion. Specimens of pleural fluids and pleural biopsy samples used for the pathologic diagnosis and the immune phenotype analyses were blindly investigated by multiparametric flow cytometry. The results were analyzed using the Kruskal-Wallis test. The Kaplan-Meier and log-rank tests were used to correlate immune phenotype data with patients' outcome. Results The cutoffs of intratumor T-regulatory (>1.1%) cells, M2-macrophages (>36%), granulocytic and monocytic myeloid-derived suppressor cells (MDSC; >5.1% and 4.2%, respectively), CD4 molecule–positive (CD4 + ) programmed death 1–positive (PD-1 + ) (>5.2%) and CD8 + PD-1 + (6.4%) cells, CD4 + lymphocyte activating 3–positive (LAG-3 + ) (>2.8% ) and CD8 + LAG-3 + (>2.8%) cells, CD4 + T cell immunoglobulin and mucin domain 3–positive (TIM-3 + ) (>2.5%), and CD8 + TIM-3 + (>2.6%) cells discriminated MPM from pleuritis with 100% sensitivity and 89% specificity. The presence of intratumor MDSC contributed to the anergy of tumor-infiltrating lymphocytes. The immune phenotype of pleural fluid cells had no prognostic significance. By contrast, the intratumor T-regulatory and MDSC levels significantly correlated with progression-free and overall survival, the PD-1 + /LAG-3 + /TIM-3 + CD4 + tumor-infiltrating lymphocytes correlated with overall survival. Conclusions A clear immune signature of pleural fluids and tissues of MPM patients may contribute to better predict patients' outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 trafficking and surface expression
Valk, E., Rudd, C. E., & Schneider, H. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.011 · Cited by 177
Cornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106742 · Cited by 91
Chéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84
Zoledronic Acid Overcomes Chemoresistance and Immunosuppression of Malignant Mesothelioma
Salaroglio, I. C., Campia, I., Kopecka, J., Gazzano, E., Orecchia, S., Ghigo, D., & Riganti, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2731 · Cited by 36 · cited 2×
“producing immune-suppressive mediators such as reactive oxygen species (ROS), nitric oxide 14 (NO) and kynurenine.(5,8,15) MDSC are killed by active CD8T-lymphocytes,(16,17) while either 15 Treg and MDSC reduce CD8T-lymphocytes activity(5,7,18) and memory CD8T-lymphocytes 16 recruitment,(19) inducing a vicious immune-…”
BackgroundSelf-citation
Cited by
Tumor-Associated Macrophages: Recent Insights and Therapies
Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., & Zhou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00188 · Cited by 619
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
“There is no expression of LAG-3 on mesothelial cells themselves (67), but high levels of LAG-3 can be detected in pleural effusions of patients with mesothelioma (68,69), and tumor infiltrating lymphocytes (TILs) in pleural effusions from patients with mesothelioma express high levels of this receptor (70).”
BackgroundThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
“, 2019 [37] 275 Intrapleural and Intratumor T-regs, M2, MDSC, TILs and OS, PFS Pleural fluid and pleural biopsies by flow cytometry MDSC related to anergy of TILs.”
BackgroundInfluentialNapoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
“Based on their surface markers, MDSC can be subdivided in granulocytic MDSC (GR-MDSC), which express granulocytic markers like CD66b and/or CD15, and monocytic MDSC (MO-MDSC), which express the monocytic antigen CD14 [91].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Salaroglio, I. C., Kopecka, J., Napoli, F., Pradotto, M., Maletta, F., Costardi, L., Gagliasso, M., Milosevic, V., Ananthanarayanan, P., Bironzo, P., Tabbò, F., Cartia, C. F., Passone, E., Comunanza, V., Ardissone, F., Ruffini, E., Bussolino, F., Righi, L., Novello, S., Di Maio, M., Papotti, M., Scagliotti, G. V., & Riganti, C.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 14
- Issue
- 8
- Pages
- 1458-1471
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2943931049
- Cited by
- 68
- References
- 4
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.